Literature DB >> 6486592

Survival in chronic hepatitis B. An analysis of 379 patients.

J I Weissberg, L L Andres, C I Smith, S Weick, J E Nichols, G Garcia, W S Robinson, T C Merigan, P B Gregory.   

Abstract

Survival data from 379 patients with chronic hepatitis B were analyzed to determine life expectancy for the patient from the time of first contact. One hundred twenty-one patients had chronic persistent hepatitis, 128 had chronic active hepatitis, and 130 had chronic active hepatitis with cirrhosis. The frequency of symptoms (p less than 0.001), stigmata of chronic liver disease (p less than 0.001), and liver function test abnormalities (p less than 0.001) increased as the histologic features worsened, whereas the percentage of patients with circulating hepatitis B DNA polymerase declined (p less than 0.001). Women were uncommon in our series and had less severe disease than men (p less than 0.02). Fifty-one patients had died by the time of this analysis. The estimated 5-year survival rates were 97% for patients with chronic persistent hepatitis, 86% for those with chronic active hepatitis, and 55% for those with chronic active hepatitis with cirrhosis. The usual cause of death was liver failure and its sequelae. A multivariate analysis found age of 40 years or more, total bilirubin level of 1.5 mg/dL or more, ascites, and spider nevi to be factors that identified patients at a higher risk of death. The prognosis for patients with chronic hepatitis B is similar to that for patients with chronic hepatitis of other causes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6486592     DOI: 10.7326/0003-4819-101-5-613

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  38 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 3.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

4.  Prediction of the prognosis of liver cirrhosis in Japanese using Cox's proportional hazard model.

Authors:  Y Tsuji; S Koga; H Ibayashi; Y Nose; K Akazawa
Journal:  Gastroenterol Jpn       Date:  1987-10

5.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

6.  Death From Liver Disease and Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection: A Prospective Study.

Authors:  Myron J Tong; Lawrence M Blatt; Kevin B Tyson; Vincent W C Kao
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

7.  Value of liver biopsy prior to interferon therapy for chronic viral hepatitis.

Authors:  T Heintges; L Mohr; F Hensel; W Petry; F Borchard; D Häussinger; C Niederau
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

Review 8.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

9.  Prognosis and life expectancy in chronic liver disease.

Authors:  A Propst; T Propst; G Zangerl; D Ofner; G Judmaier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

10.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.